Myasthenia Gravis Treatment Market (2026 - 2033)

Myasthenia Gravis Treatment Market Summary

The global myasthenia gravis treatment market size was estimated at USD 2.8 billion in 2025 and is projected to grow from USD 3.0 billion in 2026 to USD 5.1 billion by 2033, growing at a CAGR of 7.8% from 2026 to 2033. The North America market held the largest share of 50.7% of the global market in 2025. The key factors driving this market include the rising adoption of immunotherapies, the approval of promising drugs, the emergence of biologics, and increasing awareness of rare diseases.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Key Market Trends & Insights

• By treatment type: The monoclonal antibodies segment led the market with the largest revenue share of 54.8% in 2025.
• By end-use: The hospital segment led the market with the largest revenue share of 55.0% in 2025.

Regional Highlights

• Largest regional market: North America (50.7% revenue share, 2025)
• By country: The U.S. held the largest market share in 2025.

Market Size & Forecast

• Market size in 2025: USD 2.8 Billion
• Estimated market size in 2026: USD 3.0 Billion
• Projected market size by 2033: USD 5.1 Billion
• CAGR (2026-2033): 7.8%

Myasthenia gravis (MG) is a chronic, progressive, and rare neuromuscular disorder that is characterized by weakness of the head, limb, spinal, eye, and respiratory muscles. In this autoimmune disorder, antibodies are produced against the acetylcholine receptor (AchR) that impedes the normal transmission of electrical signals from nerves to muscles.

According to the National Organization for Rare Disorders (NORD), in the U.S., around 14-40 per 100,000 individuals suffer from myasthenia gravis. Reports suggest that the frequency of the disorder is on the rise over the last several decades. This can be attributed to the better identification of patients and the increasing prevalence of autoimmune disorders worldwide.

To learn more about this report, Download Free Sample Report

Myasthenia gravis occurs more frequently in females than males, and although symptoms may appear at any age, its onset usually peaks in men in their 50s or 60s and women during their 20s or 30s. There is no proven cure for myasthenia gravis; however, patients can be treated with medications and surgery to manage the symptoms.

Currently, research is focused on better understanding the specifics of the autoimmune problems associated with MG and improving their diagnosis and treatment. Additionally, the market is observing a paradigm shift in research from suppressing the immune system to rebalancing it. Another important area of research is the physiology of the neuromuscular junction (NMJ), aimed at improvement in its function regardless of probable immune system attacks.

Market Dynamics

The myasthenia gravis treatment market is evolving as healthcare providers emphasize earlier diagnosis, timely intervention, and improved disease management. Market expansion is supported by increasing awareness among healthcare professionals, growing adoption of targeted therapies, and continued investment in clinical research addressing unmet patient needs. Pharmaceutical companies are developing therapies aimed at improving symptom control, enhancing patient outcomes, and reducing treatment burden. Recent regulatory approvals and expanded treatment options have broadened the therapeutic landscape and created opportunities across major healthcare markets. Market dynamics are influenced by treatment accessibility, reimbursement policies, pricing considerations, and competition between conventional therapies and newer biologic products. The increasing availability of advanced therapies is supporting broader adoption, particularly in regions with established healthcare infrastructure. Ongoing research activity, supportive regulatory pathways, and a growing focus on personalized treatment approaches are expected to contribute to continued market development and sustained innovation within the myasthenia gravis treatment market.

Analyst Perspective

The myasthenia gravis treatment market is undergoing a transition from conventional immunosuppressive therapies toward targeted biologics and precision driven treatment approaches. Recent regulatory approvals of FcRn inhibitors, complement inhibitors, and other immune targeted therapies are expanding treatment options and improving disease management for specific patient populations. Market growth is supported by increasing disease awareness, improved diagnostic capabilities, and ongoing investments in rare disease research. However, high treatment costs and reimbursement challenges may continue to influence adoption rates across healthcare systems. Looking ahead, continued innovation in biologics, antibody specific therapies, and advanced immunomodulatory approaches is expected to shape the competitive landscape and create opportunities for market expansion.

Treatment Type Insights

Medications can dramatically inhibit the immune system and largely manage the associated symptoms. Medications include immunotherapies such as Soliris (eculizumab), corticosteroids, and immunosuppressive drugs such as Prograf (tacrolimus) and Neoral/Sandimmune (cyclosporine). The other major treatment alternative, surgery, is the most invasive and usually involves a thymectomy (thymus removal). The thymus deteriorates with age (thymic involution); however, complete loss of the thymus in such a manner will significantly weaken a patient’s immune system.

Based on treatment type, the monoclonal antibodies segment led the market with the largest revenue share of 54.8% in 2025, owing to the high precision in treating myasthenia gravis and better efficacy. For instance, Alexion Pharmaceuticals’ eculizumab monoclonal antibodies drug Soliris is used for the treatment of myasthenia gravis. Recently, it received approval from the U.S. Food and Drug Administration (FDA) and the European Commission for treating adult patients with generalized myasthenia gravis who are anti-AchR antibody-positive. Soliris is the first and only complement inhibitor approved for this disorder. The increasing use of monoclonal antibodies and immunosuppressants is aimed at reducing lifelong exposure to corticosteroids and improving long-term results.

The market is witnessing an upsurge in the number of pipeline studies for drug development that is expected to drive the market, resulting in an anticipated fastest growth of 41.8% CAGR in the pipeline studies segment over the forecast period.

End-use Insights

Based on end use, the market has been segmented into hospitals, clinics, and others. The hospital segment led the market with the largest revenue share of 55.0% in 2025 and is expected to grow at a lucrative CAGR of 9.0% over the forecast period. This can be attributed to access to a large patient pool and the high demand for advanced equipment for MG treatment in hospital settings. There has been an increase in patient visits for diagnosis and treatment of MG due to the availability of a broad range of treatment options in such facilities. Furthermore, one of the major factors contributing to its large share is the increased investment in state-of-the-art healthcare infrastructures.

To learn more about this report, Download Free Sample Report

The clinic segment held the second-largest share of around 30% in 2022 and is expected to retain the position through the forecast period. With the growing need for specialized treatments, many patients prefer specialty clinics for rapid diagnosis and effective MG treatment. A large segment of the end users also depend on eCommerce channels for obtaining therapeutics for myasthenia gravis. These segments are significantly contributing to the growth of the myasthenia gravis treatment market.

Regional Insights

North America dominated the myasthenia gravis treatment market with the largest revenue share of 50.7% in 2025. This can be attributed to the high adoption of immunotherapies and monoclonal antibodies, increasing healthcare expenditure, the presence of established research and development facilities, and favorable reimbursement scenarios.

To learn more about this report, Download Free Sample Report

U.S. Myasthenia Gravis Treatment Market Trends

The myasthenia gravis treatment marketin the U.S. held the largest share in the North America region in 2025

Middle East and Africa is expected to grow at the fastest CAGR of 14.9% over the forecast period. This can be attributed to the rising prevalence of myasthenia gravis in the region, especially among the elderly population, increasing awareness, availability of advanced diagnostics tools and therapeutic options, and the expansion of healthcare infrastructure.

Asia Pacific is anticipated to grow at a lucrative CAGR through the forecast period due to the increase in revenue generation from medications such as immunosuppressants and monoclonal antibodies in this region. Other factors propelling the growth are the initiatives associated with increasing investments in the healthcare sector by the regional governments and manufacturers.

Key Companies & Market Share Insights

Some of the key companies operating in the market such as Alexion Pharmaceuticals and Astellas Pharma hold the largest market shares due to the strong sales of their flagship products, including Soliris and Prograf.

However, generic competition is a major hindrance to market growth due to the patent loss of several marketed products and the availability of low-priced substitutes to branded drugs in the market. To gain an advantage against competitors, companies are adopting strategies such as expansion in emerging countries, new product development, spreading awareness, and getting into collaborations. For instance, in April 2022, AstraZeneca received approval for Ultomiris (ravulizumab-cwvz) from the FDA for generalized myasthenia gravis. In December 2021, the FDA approved efgartigimod drug Vyvgart, a novel treatment for AChR positive tested generalized myasthenia gravis patients.

Key Myasthenia Gravis Treatment Companies:

The following key companies have been profiled for this study on the myasthenia gravis treatment market.

• Alexion Pharmaceutical Inc.

• Grifols SA

• Avadel Pharmaceuticals, Plc.

• Novartis

• Pfizer, Inc.

• AbbVie Inc.

• F.Hoffmann-La Roche AG

• GlaxoSmithKline Plc.

• Bausch Health Companies Inc.

• Shire plc

Global Myasthenia Gravis Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global myasthenia gravis treatment market based on treatment type, end-use, and region:

To learn more about this report, Download Free Sample Report

• Treatment Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Cholinesterase Inhibitors

  • Chronic Immunomodulators

  • Monoclonal Antibodies

  • Rapid Immunotherapies

  • Thymectomy

  • Others

• End-use Outlook (Revenue, USD Million, 2021 - 2033)

  • Hospitals

  • Clinics

  • Others

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Sweden

    • Norway

    • Denmark

  • Asia Pacific

    • China

    • Japan

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa

    • Saudi Arabia

    • South Africa

    • UAE

    • Kuwait

Research Methodology

The myasthenia gravis treatment market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing - reconciling supply-side and demand-side estimates - and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each myasthenia gravis treatment segment quantified using the revenue-capture definitions in the table below.

Estimation Model

The Myasthenia Gravis (MG) Treatment Market size is estimated to use a patient-based epidemiology and revenue modeling approach. The methodology begins with analyzing the total population across major regions and countries, followed by identifying the prevalence and incidence of myasthenia gravis through published epidemiological studies, patient registries, healthcare databases, and scientific literature. The total patient pool is then refined to estimate the diagnosed population by considering disease awareness, access to healthcare services, and diagnostic rates. Subsequently, the treated patient population is assessed based on treatment uptake patterns and access to available therapies. The treated population is further segmented by therapy type, including acetylcholinesterase inhibitors, corticosteroids, immunosuppressants, intravenous immunoglobulin (IVIG), plasma exchange, complement inhibitors, FcRn inhibitors, and other emerging biologic treatments. The average annual cost of each therapy is calculated using drug pricing data, treatment duration, administration costs, reimbursement policies, and regional healthcare expenditure trends. Market revenue is derived by multiplying the number of patients receiving each therapy by the corresponding annual treatment cost and aggregating revenues across all treatment segments and geographies. The final market estimates are validated through primary interviews with neurologists, hospital pharmacists, key opinion leaders, and industry participants, while data triangulation using both top-down and bottom-up approaches ensures the accuracy and reliability of the market size and forecast.

Delivered Customizations

This report has been delivered with the following In-depth customizations